

Summary of Study Results

1. Capomulin Performance:

- Capomulin was effective in reducing tumor size over time compared to other treatment regimens.
- Results showed a significant reduction in tumor volume in mice treated with Capomulin, suggesting it's a viable treatment source for SCC tumors.

2. Survival Rates:

- Mice treated with Capomulin had higher survival rates over the study period compared to those on other treatments.
- Most other regimens, including Infubinol, Ketapril, and Zoniferol, have higher mean tumor volumes (above 50), indicating less effectiveness in tumor reduction.

3. Safety and Side Effects:

- No severe adverse effects associated with Capomulin were observed, supporting its potential safety for further development.

Conclusion

The study highlights Capomulin as the leading, promising candidate for SCC tumor treatment, outperforming many alternative regimens in terms of tumor reduction and overall survival.